Fidelity Investments
ACRV icon

Fidelity Investments’s Acrivon Therapeutics ACRV Stock Holding History

Fidelity Investments’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.1K Buy
9,422
+800
+9% +$1.4K ﹤0.01% 4679
2025
Q4 		$20.8K Hold
8,622
– – ﹤0.01% 4448
2025
Q3 		$15.6K Sell
8,622
-1,228
-12% -$1.73K ﹤0.01% 4453
2025
Q2 		$11.7K Buy
9,850
+7,185
+270% +$9.86K ﹤0.01% 4486
2025
Q1 		$5.41K Sell
2,665
-268
-9% -$1.44K ﹤0.01% 4676
2024
Q4 		$17.7K Buy
2,933
+352
+14% +$2.56K ﹤0.01% 4231
2024
Q3 		$18.1K Buy
2,581
+933
+57% +$7.35K ﹤0.01% 4221
2024
Q2 		$9.56K Buy
1,648
+621
+60% +$5K ﹤0.01% 4345
2024
Q1 		$7.34K Buy
1,027
+221
+27% +$1.03K ﹤0.01% 4382
2023
Q4 		$3.97K Buy
806
+518
+180% +$2.74K ﹤0.01% 4513
2023
Q3 		$2.75K Sell
288
-134
-32% -$1.55K ﹤0.01% 4464
2023
Q2 		$5.47K Buy
422
+300
+246% +$3.63K ﹤0.01% 4340
2023
Q1 		$1.55K Buy
+122
New +$2.05K ﹤0.01% 4683

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments's ACRV Position: Q1 2026 in Review

Fidelity Investments increased its Acrivon Therapeutics (ACRV) stake by 9.3% in Q1 2026, buying an estimated $1.4K and bringing the position to 9,422 shares worth $13.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4679.

Fidelity Investments first reported a position in ACRV in Q1 2023 and has held it in 13 quarters since. The position peaked at $20.8K in Q4 2025. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

  • Fidelity Investments held 9,422 shares of Acrivon Therapeutics worth $13.1K as of Q1 2026.
  • Fidelity Investments bought 800 Acrivon Therapeutics shares in Q1 2026, an estimated $1.4K.
  • Acrivon Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4679 holding.
  • Fidelity Investments first reported a position in Acrivon Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Fidelity Investments's Acrivon Therapeutics position peaked at $20.8K in Q4 2025.
  • 44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.